mRNA-2416 encodes OX40L, dosed alone or in combination with the intravenously administered PD-L1 inhibitor durvalumab for the treatment of lymphoma and metastatic ovarian cancer (NCT03323398). The gene discussed is TNFSF4; the disease is lymphoma.